1. Цой А.Н., Архипов В.В., Чапурин С.А., Чурилин Ю.Ю. Фармакоэкономическое исследование новой концепции применения Симбикорта у больных бронхиальной астмой. Пульмонология. 2007; 3: 34–40.
2. Adcock I, Maneechotesuwan K, Usmani O. Molecular interaction between glucocorticoids and long-acting β2 agonists. J Allergy Clin Immunol 2002; 110 (6, suppl.): 261s–8s.
3. Adcock IM. Molecular mechanisms of glucocorticoid actions. Pulm Pharm Ther 2000; 13 (3): 115–26.
4. Anderson GP, Linden A, Rabe KF. Why are long-acting beta-adrenoceptor agonists long acting ? Eur Respir J 1994; 7 (3): 569–78.
5. Balanag VM, Yunus F, Yang P-C, Jorup C. Efficacy and safety of budesonide/formoterol compared with salbutamol in treatment of acute asthma. Pulm Pharm Ther 2006; 19: 139–47.
6. Barnes PJ, Pedersen S, Busse WW. Efficacy and safety of inhaled corticosteroids. New development. Am J Respir Crit Care Med 1998; 157 (3, pt 2): 1S–53S.
7. Barnes PJ. Scientific rationale for combination inhalers with a long-acting and β2-agonists and corticosteroids. Eur Respir J 2002; 19 (1): 182–91.
8. Barnes PJ. Scientific rationale for using single inhaler for asthma control. Eur Respir J 2007; 29 (3): 587–95.
9. Bateman ED, Boushley HA, Bousquet J et al. Can guideline-defined asthma control be achieved? The Gaining Optimal Asthma Control Study. Am J Respir Crit Care Med 2004; 170: 836–44.
10. Bousquet J, Boulet L-P, Peters MJ et al. Budesonide/formoterol for maintenance and relief in uncontrolled asthma vs high dose salmeterol/fluticasone. Respir Medicine 2007; 101 (12): 2437–46.
11. Cazzola M, Imperatore F, Salzillo A et al. Cardiac effects of formoterol and salmeterol in patients suffering from COPD with preexisting cardiac arrythmias and hypoxemia. Chest 1998; 114: 411–5.
12. Cazzola M, Matera MG, Donner CF. Inhaled beta2-adrenoreceptor agonists: cardiovascular safety in patients with obstructive lung disease. Drugs 2005; 65 (12): 1595–610.
13. Erin EM, Zachrasiewicz AS, Nicholson GC et al. Topical corticosteroid inhibits interleukin 4,5 and 13 in nasal secretions following allergen challenge. Clin Exp Allergy 2005; 35 (12): 1608–14.
14. Ferrari M, Balestreri F, Baratieri S et al. Evidence of the rapid protective effect of formoterol dry-powder inhalation against exercise-induced bronchospasm in athletes with asthma. Respiration 2000; 67 (5): 510–3.
15. Forensi A, Morelli MC, Catena E. Low dose budesonide with the addition of increased dose during exacerbations is effective in long-term asthma control. Chest 2000; 117 (2): 440–6.
16. Gibson PJ, Saltos N, Fakes K. Acute anti-inflammatory effect of inhaled budesonide in asthma. A randomized controlled trial. Am J Respir Crit Care Med 2001; 163 (1): 32–6.
17. Global Initiative for Аsthma. NHLB/WHO Workshop Report.-National Heart Lung Blood Institute, Publication number 02–3659, revised 2006. Пер. с англ. Под ред. А.Г.Чучалина. М.: Атмосфера, 2007.
18. Guhan AR, Cooper S, Oborne J et al. Systemic effect of formoterol and salmeterol: a dose-response comparison in healthy subjects. Thorax 2000; 55: 650–6.
19. Ind PW, Villasante C, Shiner RJet al. Safety of formoterol by Turbuhaled as reliver medication compared with terbutaline in moderate asthma. Eur Respir J 2002; 20 (4): 859–66.
20. Johansson G, Andreasson EB, Larsson PE, Vogelmeier CF. Cost effectiveness of budesonide/formoterol for maintenance and reliever therapy versus salmeterol/fluticasone plus salbutamol in the treatment of аsthma. Pharmacoeco-nomics 2006; 24 (7): 695–708.
21. Ketchell RI, Jensen MW, Lumley P et al. Rapid effect of inhaled fluticasone propionate on airway hyperresponsiveness to adenosine 5-monophosphate in mild asthma. J Allegry Clin Immunol 2002; 110 (4): 603–6.
22. Ketchell RI, Jensen MW, Spina D et al. Dose-related effects of formoterol on airway hyperresponsiveness to adenosine 51 monophosphate and histamine. Eur Respir J 2002; 19 (4): 611–6.
23. Kuna P, Peters MJ, Manjra AI et al. Effect of budesonide/formoterol maintenance and reliever therapy on asthma exacerbations. Int J Clin Pract 2007; 61 (5): 725–36.
24. Maneechotesuwan K, Essilfie-Quaye S, Meah S et al. Formoterol attenuates neutrophilic airway inflammation in asthma. Chest 2005; 128 (4): 1936–42.
25. Nightingale JA, Rogers DF, Barnes PJ. Differential effect of formoterol on adenosine monophosphate and histamine reactivity in asthma. Am J Respir Crit Care Med 1999; 159 (6): 1786–90.
26. O'Byrne P, Bisgaard H, Godard PP et al. Budesonide/Formoterol combination therapy as both meintenance and reliever medication in asthma. Am J Respir Crit Care Med 2005; 171 (2): 129–36.
27. Palmqvist M, Persson G, Lazer L et al. Inhaled dry-powder formoterol and salmeterol in asthmatic patients: onset of action, duration of effect and potency. Eur Respir J 1997; 10 (11): 2484–9.
28. Partridge MR, van Molen T, Myrseth S-E, Busse WW. Attitude and actions of asthma patients on regular maintenance therapy: the INSPIRE study. BMC Pulmonary Medicine 2006; 6: 13.
29. Pauwells RA, Lofdahl C-G, Postma D et al. Effect of inhaled formoterol and budesonide on exacerbations of asthma. N Engl J Med 1997; 337 (20): 1412–8.
30. Pauwels RA, Sears MR, Campbell M et al. Formoterol as relief medication in asthma: a worldwide safety and effectiveness trial. Eur Respir J 2003; 22: 787–94.
31. Price D, Wiren A, Kuna P. Cost-effectiveness of budesonide/formoterol for maintenance and reliever asthma therapy. Allergy 2007; 62 (10): 1189–98.
32. Rabe K, Pizzichini E, Stallberg B et al. Budesonide/Formoterol in a single inhaler for maintenance and relief in mild-to-moderate asthma. A randomized, double blind trial. Chest 2006; 129 (2): 246–56.
33. Rabe KF, Atienza T, Magyar P et al. Effect of budesonide in combination with formoterol for reliver therapy in asthma exacerbations: a randomised controlled, double blind study. Lancet 2006; 368: 744–53.
34. Rosenborg J, Bengtsson T, Larsson P et al. Relative systemic dose potency and tolerability of inhaled formoterol and salbutamol in healthy subjects and asthmatics, Eur J Clin Pharmacol 2000; 56 (5): 363–70.
35. Scicchitano R, Aalbers R, Ukena D et al. Efficacy and safety of budesonide/formoterol single inhaler therapy versus a higher dose of budesonide in moderate to severe asthma. Curr Med Res Opin 2004; 20 (9): 1403–18.
36. Stahl E, Postma DS, Svensson K et al. Formoterol used as needed improves health-related quality of life in asthmatic patients uncontrolled with inhaled corticosteroids. Respir Med 2003; 97 (9): 1061–6.
37. Tatersfield AE, Lofdahl CG, Postma DS et al. Comparison of formoterol and terbutaline for as-needed treatment of asthma: a randomized trial. Lancet 2001; 357 (9252): 257–61.
38. Tatersfield AE, Postma DS, Barnes P et al. Exacerbations of asthma. A descriptive study of 425 severe exacerbations. Am J Respir Crit Care Med 1999; 160 (2): 594–9.
39. Vogelmeier C, D'Urzo A, Pauwels R et al. Budesonide/formoterol maintenance and reliever therapy: an effective asthma treatment option? Eur Respir J 2005; 26 (5): 819–28.
40. Wark PAB, Gibson PG. Asthma exacerbation. 3 Pathogenesis. Thorax 2006; 61 (11): 909–15.